Velaglucerase Alfa is a recombinant human lysosomal enzyme used as an enzyme replacement therapy for the long-term treatment of patients with Type 1 Gaucher disease. It is a recombinant form of human β-glucocerebrosidase, the enzyme responsible for hydrolysing glucocerebroside into glucose and ceramide. In Gaucher disease, deficiency of this enzyme results in the accumulation of glucocerebroside within lysosomes, particularly in macrophages. Velaglucerase Alfa replaces the deficient enzyme and supports the breakdown of accumulated glucocerebroside.
Velaglucerase Alfa is a 497-amino-acid glycoprotein with an approximate molecular weight of 63 kDa. It is produced using recombinant DNA technology in a human fibroblast cell line. The amino acid sequence is the same as the naturally occurring human glucocerebrosidase enzyme. The molecule contains five potential N-linked glycosylation sites, with four occupied by glycan chains, predominantly high-mannose-type N-linked glycans.
The enzyme's biological activity is measured in Units, rather than by the conventional percentage HPLC assay normally used for small-molecule APIs. One Unit of Velaglucerase Alfa enzyme activity is defined as the amount of enzyme required to convert one micromole of p-nitrophenyl β-D-glucopyranoside to p-nitrophenol per minute at 37°C.
Commercial VPRIV is supplied as a sterile, preservative-free, white to off-white lyophilized powder in single-dose vials. The currently documented 400-Unit vial contains Velaglucerase Alfa together with sucrose, sodium citrate dihydrate, citric acid monohydrate and polysorbate 20. After reconstitution with 4.3 mL Sterile Water for Injection, the resulting concentration is 100 Units/mL and the pH is approximately 6.0.
The 400-Unit presentation contains 400 Units of Velaglucerase Alfa, 200 mg sucrose, 51.76 mg sodium citrate dihydrate, 5.04 mg citric acid monohydrate and 0.44 mg polysorbate 20. Historical EMA assessment documentation also describes 200-Unit and 400-Unit presentations corresponding to 5 mg and 10 mg of drug substance, respectively.
Velaglucerase Alfa belongs to the therapeutic category of enzyme replacement therapies. It is specifically indicated for long-term enzyme replacement therapy in patients with Type 1 Gaucher disease. The FDA approved VPRIV for treatment of Type 1 Gaucher disease, and the EMA lists the same therapeutic indication.
From a pharmaceutical manufacturing and quality perspective, Velaglucerase Alfa requires a biologics-specific quality-control strategy. Important quality attributes include molecular identity, protein concentration, enzymatic activity, purity, aggregation, charge variants, glycosylation profile, host-cell-derived impurities, residual process-related impurities, endotoxin and microbiological quality. These attributes should be controlled using validated analytical methods and product-specific acceptance criteria.
Because Velaglucerase Alfa is a recombinant protein, conventional small-molecule parameters such as melting point, residue on ignition, specific rotation and percentage HPLC assay are not appropriate universal release specifications. The applicable specifications should therefore be established according to the approved biologic product specification and validated manufacturing process.
Velaglucerase Alfa is therefore an important recombinant enzyme for pharmaceutical and biopharmaceutical development associated with lysosomal storage disorders and enzyme replacement therapy. A qualified Velaglucerase Alfa manufacturer and supplier in India should maintain appropriate controls for biological activity, protein quality, identity, purity, glycosylation and microbiological safety.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |